Document is current
Any future updates will be listed below
-
Authors
Merli, Pietro https://orcid.org/0000-0001-6426-4046
Massa, Michele
Russo, Alessandra
Rea, Francesca
Del Chierico, Federica
Galaverna, Federica
Del Bufalo, Francesca
Pane, Stefania
Algeri, Mattia
Romeo, Erminia Francesca
Masucci, Luca
De Angelis, Paola
Putignani, Lorenza
Locatelli, Franco https://orcid.org/0000-0002-7976-3654
-
Funding
Funding for this research was provided by:
Ministero della Salute (GR-2013-02357136, GR-2018-12368106)
- License Information
-
More Information
Article History
Received: 19 May 2022
Revised: 20 June 2022
Accepted: 27 June 2022
First Online: 14 July 2022
Competing interests
: PM reports personal fees from Sobi and Jazz, outside the submitted work. MA served on Scientific Advisory Board for Vertex Pharmaceuticals and as Steering Committee member for Vertex Pharmaceuticals, outside the submitted work. FL reports personal fees from Amgen, personal fees from Novartis, other from Bellicum Pharmaceutical, other from Neovi, personal fees from Miltenyi, personal fees from Medac, personal fees from Jazz Pharmaceutical, personal fees from Takeda, outside the submitted work.
